News Sernova Toronto S.E.

Stocks

SVA

CA81732W1041

Medical Equipment, Supplies & Distribution

Market Closed - Toronto S.E. 20:10:34 04/09/2026 BST			5-day change	1st Jan Change
0.1100 ^CAD	-4.35%		0.00%	-15.38%

06-17	Sernova's Autologous Islet Transplantation Gets Orphan Drug Designation For Type 3c Diabetes Prevention	MT
06-11	Sernova Biotherapeutics Inc Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI

All News

Mentions Relevance

06-17	Sernova's Autologous Islet Transplantation Gets Orphan Drug Designation For Type 3c Diabetes Prevention	MT
06-17	Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy	AQ
06-11	Sernova Biotherapeutics Inc Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
04-23	Sernova Biotherapeutics Announces Closing of Recently Approved Financings	NE
04-22	Sernova Biotherapeutics Inc announced that it has received CAD 7.564399 million in funding	CI
04-09	Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders	NE
03-24	Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing	NE
03-16	Sernova Biotherapeutics : 2026 Q1 MD&A	PU
03-16	Sernova Biotherapeutics : 2026 Q1 Financial Statements	PU
03-13	Sernova Biotherapeutics Inc Reports Earnings Results for the First Quarter Ended January 31, 2026	CI
03-09	Sernova Biotherapeutics : Appointment of Proxyholder (SVA 2026 Proxy)	PU
03-09	Sernova Biotherapeutics : Voting Instruction Form (VIF) (SVA 2026 VIF)	PU
03-09	Sernova Biotherapeutics : Combined Circular with Schedules (SVA 2026 Combined Circular w Schedules)	PU
03-04	Sernova Biotherapeutics Inc announced that it expects to receive CAD 7.1 million in funding	CI
03-04	Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval	NE
02-20	Sernova Biotherapeutics Announces Warrant Amendments	NE
01-12	Sernova Biotherapeutics : 2025 Annual Information Form	PU
01-12	Sernova Biotherapeutics : 2025 Q4 MD&A	PU
01-12	Sernova Biotherapeutics : 2025 Q4 Financial Statements	PU
12-19	Sernova Biotherapeutics Inc Reports Earnings Results for the Full Year Ended October 31, 2025	CI
12-18	Sernova Biotherapeutics Inc Auditor Raises 'Going Concern' Doubt	CI
11-13	Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts	NE
11-12	Sernova Biotherapeutics Inc announced that it expects to receive CAD 5 million in funding	CI
01/10/25	Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang	NE
23/09/25	Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors	AQ